

Giacomo Cafaro

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8030552/giacomo-cafaro-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42
papers

524
citations

12
h-index

21
g-index

52
ext. papers

731
ext. citations

3.6
avg, IF

4.21
L-index

#	Paper	IF	Citations
42	Unattended compared to traditional blood pressure measurement in patients with rheumatoid arthritis: a randomised cross-over study. <i>Annals of Medicine</i> , 2021 , 53, 2050-2059	1.5	1
41	Peripheral Nervous System Involvement in Sjögren's Syndrome: Analysis of a Cohort From the Italian Research Group on Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2021 , 12, 615656	8.4	1
40	Novel self-amplificatory loop between T cells and tenocytes as a driver of chronicity in tendon disease. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	8
39	Contribution of Janus-Kinase/Signal Transduction Activator of Transcription Pathway in the Pathogenesis of Vasculitis: A Possible Treatment Target in the Upcoming Future. <i>Frontiers in Pharmacology</i> , 2021 , 12, 635663	5.6	4
38	Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections. <i>Microorganisms</i> , 2021 , 9,	4.9	8
37	An Italian Disease-Based Registry of Axial and Peripheral Spondyloarthritis: The SIRENA Study. <i>Frontiers in Medicine</i> , 2021 , 8, 711875	4.9	0
36	Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	
35	One year in review 2021: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021 ,	2.2	3
34	Traditional and disease-related non-computed variables affect algorithms for cardiovascular risk estimation in Sjögren's syndrome and rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 107-113	2.2	0
33	One year in review 2021: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 3-13	2.2	2
32	THU0257 ESTIMATED 10-YEARS CARDIOVASCULAR RISK IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: PRELIMINARY RESULTS FROM THE CARDIOVASCULAR OBESITY AND RHEUMATIC DISEASE (CORDIS) STUDY GROUP OF THE ITALIAN SOCIETY OF RHEUMATOLOGY.. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 3552-356	2.4	
31	COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. <i>Immunologic Research</i> , 2020 , 68, 213-224	4.3	90
30	Hypertension and SARS-CoV-2 infection: is inflammation the missing link?. <i>Cardiovascular Research</i> , 2020 , 116, e193-e194	9.9	3
29	Association Between Glandular Infiltrate and Leukopenia in Sjögren Syndrome (SS): Data From the Italian Research Group on SS (GRISS). <i>Journal of Rheumatology</i> , 2020 , 47, 1840-1841	4.1	4
28	Salivary Gland Ultrasonography in Sjögren's Syndrome: A European Multicenter Reliability Exercise for the HarmonicSS Project. <i>Frontiers in Medicine</i> , 2020 , 7, 581248	4.9	8
27	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. <i>Journal of Autoimmunity</i> , 2020 , 111, 102468	15.5	76
26	The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 580	2.2	6

25	Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 754-759	2.2	26
24	One year in review 2020: comorbidities, diagnosis and treatment of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 10-22	2.2	10
23	Significance of anti-La/SSB antibodies in primary Sjögren's syndrome patients with combined positivity for anti-Ro/SSA and salivary gland biopsy. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 53-56	2.2	
22	Subclinical Atherosclerosis in Primary Sjögren's Syndrome: Does Inflammation Matter?. <i>Frontiers in Immunology</i> , 2019 , 10, 817	8.4	6
21	Effect of Sinovial High-Low□ injections in trapeziometacarpal osteoarthritis. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 166	2.2	4
20	One year in review 2019: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 3-15	2.2	13
19	Application of artificial neural network analysis in the evaluation of cardiovascular risk in primary Sjögren's syndrome: a novel pathogenetic scenario?. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 133-139	2.2	1
18	A Platelet's Guide to Synovitis. <i>Israel Medical Association Journal</i> , 2019 , 21, 454-459	0.9	0
17	Psoriatic arthritis: tissue-directed inflammation?. <i>Clinical Rheumatology</i> , 2018 , 37, 859-868	3.9	15
16	Association between anti-citrullinated alpha enolase antibodies and clinical features in a cohort of patients with rheumatoid arthritis: a pilot study. <i>Reumatismo</i> , 2018 , 70, 67-71	1.1	3
15	Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality?. <i>Frontiers in Cardiovascular Medicine</i> , 2018 , 5, 177	5.4	9
14	Extra-articular rheumatoid arthritis. <i>Reumatismo</i> , 2018 , 70, 212-224	1.1	25
13	Prevalence and significance of anti-saccharomyces cerevisiae antibodies in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 73-79	2.2	2
12	The prevalence and relevance of traditional cardiovascular risk factors in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 113-120	2.2	6
11	One year in review 2018: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 14-26	2.2	10
10	Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 210-214 ²	2.2	2
9	The clinical spectrum of primary Sjögren's syndrome: beyond exocrine glands. <i>Reumatismo</i> , 2017 , 69, 93-100	1.1	6
8	Insulin-Like Growth Factor Binding Protein 6 in Rheumatoid Arthritis: A Possible Novel Chemotactic Factor?. <i>Frontiers in Immunology</i> , 2017 , 8, 554	8.4	14

7	One year in review 2017: pathogenesis of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 368-378	2.2	72
6	Central Hemodynamics and Arterial Stiffness in Systemic Sclerosis. <i>Hypertension</i> , 2016 , 68, 1504-1511	8.5	12
5	The onset site of rheumatoid arthritis: the joints or the lung?. <i>Reumatismo</i> , 2016 , 68, 167-175	1.1	4
4	One year in review 2016: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 161-71	2.2	20
3	Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 1727-37	5.4	24
2	Serum interleukin-17 in primary Sjögren's syndrome: association with disease duration and parotid gland swelling. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 129	2.2	15
1	Drugs in induction and treatment of idiopathic inflammatory myopathies. <i>Autoimmunity Highlights</i> , 2014 , 5, 95-100	3.7	5